Search results
Results from the WOW.Com Content Network
Current HIV Research is a peer-reviewed scientific journal focusing on HIV/AIDS research, established in 2003. The journal is edited by Yuntao Wu and is published by Bentham Science Publishers . It has an impact factor of 1.581
HIV/AIDS: Research and Palliative Care is a peer-reviewed medical journal covering HIV and its treatment. The journal was established in 2009 and is published by Dove Medical Press. It is abstracted and indexed in PubMed, EMBASE, EmCare, and Scopus.
AIDS is a peer-reviewed scientific journal that is published by Lippincott Williams & Wilkins. It was established in 1987 and is an official journal of the International AIDS Society. [1] It covers all aspects of HIV and AIDS, including basic science, clinical trials, epidemiology, and social science. The editor in chief is Jay A. Levy ...
Scanning electron micrograph of HIV-1, colored green, budding from a cultured lymphocyte Diagram of HIV. HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.
HIV Medicine is a bimonthly peer-reviewed medical journal covering HIV/AIDS research. It was established in 1999 and is published by Wiley-Blackwell on behalf of the British HIV Association, of which it is the official journal. It is also the official journal of the European AIDS Clinical Society and the Australasian Society for HIV Medicine. [1]
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
HIV-1 protease is one of the best known aspartic proteases, and an attractive target for the treatment of AIDS. [9] After the discovery of HIV protease it only took 10 years for its first inhibitor to reach the market. [10] The first reports of highly selective antagonists against the HIV protease were revealed in 1987.
The human immunodeficiency virus (HIV) [8] [9] [10] is a retrovirus [11] that attacks the immune system.It is a preventable disease. [5] There is no vaccine or cure for HIV. It can be managed with treatment and become a manageable chronic health condition. [5]